Gilead Sciences (GILD) Files Patent Infringement Suit Against Teva Pharmaceuticals (TEVA)
More News related to GILD
- Gilead Sciences to Present at the Lazard Capital Markets 6TH Annual Healthcare Conference on Tuesday, November 17
- Gilead Sciences to Present at the 18th Annual Credit Suisse Healthcare Conference on Wednesday, November 11
- Trading Outlook for MannKind Corp. Issued by InvestorSoup.com
- Gilead Sciences (GILD) and Glaxo (GSK) Announce Pulmonary Arterial Hypertension Clinical Trial
- Gilead Sciences Announces Plans for Phase IV Clinical Trial Evaluating First-Line Combination Therapy Versus Monotherapy in Pulmonary Arterial Hypertension
More News related to TEVA
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
- Teva Receives Final Approval for Generic Prevacid(R) Delayed-Release Capsules
- Teva Pharma (TEVA) Announces Generic Version of Prevacid Does Not Infringe on Patents
- Teva Receives Favorable Court Decision Regarding Generic Prevacid(R) SoluTab
- Teva Pharma (TEVA) Seeks to Amend Existing Complaint Against Momenta Pharma over Copaxone Patent Infringement
More News related to Corporate News
- S&P Announces Changes to US Index: CMN for NTG, CVGW for STSA
- Kinross (KGC) Enters Agreement for $125M Letter of Credit Facility
- Endo Pharma (ENDP) Announces Settlement with LecTec Over Outstanding Patent Litigation
- Trubion Pharma (TRBN) Announces Two Presentations of TRU-016 Product at 2009 ASH Meeting
- S&P Revises Outlook on Sirius XM (SIRI) from Stable to Positive
Gilead Sciences, Inc. (Nasdaq: GILD) has filed a lawsuit in U.S. District Court in New York against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd. (Nasdaq: TEVA) for infringement of U.S. Patent Numbers 6,642,245 and 6,703,396. Both patents are associated with emtricitabine, a component of Truvada, and are licensed exclusively to Gilead Sciences by Emory University. Truvada is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.
The lawsuit is based on an Abbreviated New Drug Application filed by Teva Pharmaceuticals USA, Inc., which seeks approval to manufacture and market a generic version of Truvada before the expiration of both emtricitabine patents.
Gilead Sciences, Inc. (Gilead) is a biopharmaceutical company that discovers, develops and commercializes therapeutics in areas of unmet medical need. [SM]
Related Categories
Corporate NewsStocks Mentioned
+0.33
-0.21Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
